These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31072401)

  • 1. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
    Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
    Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
    Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
    Muller A; Vlahov D; Akiyama MJ; Kurth A
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia.
    Luhmann N; Champagnat J; Golovin S; Maistat L; Agustian E; Inaridze I; Myint WM; Butsashvili M; Bouscaillou J
    Int J Drug Policy; 2015 Nov; 26(11):1081-7. PubMed ID: 26342273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.
    Smith DJ; Combellick J; Jordan AE; Hagan H
    Int J Drug Policy; 2015 Oct; 26(10):911-21. PubMed ID: 26298331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
    Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
    Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable.
    McDonald SA; Myring G; Palmateer NE; McAuley A; Beer L; Dillon JF; Hollingworth W; Gunson R; Hickman M; Hutchinson SJ
    Addiction; 2023 Jul; 118(7):1340-1350. PubMed ID: 36808787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
    Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
    Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H
    PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urgent action to fight hepatitis C in people who inject drugs in Europe.
    Dillon JF; Lazarus JV; Razavi HA
    Hepatol Med Policy; 2016; 1():2. PubMed ID: 30288305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
    Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
    Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.